Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | FABP4 | P15090 | 1/20 | 0.59 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.59 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591847 | 0.90 | FABP4 (0.72) | BCHEMEN1KMT2AL3MBTL1FABP4 | |
| SCHEMBL5017858 | 0.89 | FABP4 (0.59) | BCHEMEN1KMT2AL3MBTL1FABP4 | |
| SCHEMBL28129137 | 0.88 | BCHE (0.59) | BCHEMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL9802314 | 0.88 | L3MBTL1 (0.69) | BCHEMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL8733917 | 0.86 | SCN9A (0.53) | — | |
| SCHEMBL13888119 | 0.85 | BCHE (0.69) | BCHEMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL6036164 | 0.84 | FABP4 (0.52) | MEN1KMT2AKDM4EFABP4FABP5 | |
| SCHEMBL6035893 | 0.84 | BCHE (0.68) | BCHEMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL991380 | 0.83 | KMT2A (0.54) | MEN1KMT2AKDM4EFABP4FABP5 | |
| SCHEMBL29639215 | 0.83 | KMT2A (0.54) | MEN1KMT2AKDM4EFABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000022909-A2 | SYSTEMS FOR ORAL DELIVERY | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | BCHE 1107/4885MEN1 2048/4885KMT2A 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.